97 related articles for article (PubMed ID: 16019521)
1. Granulocyte colony-stimulating factor (G-CSF) could enhance Fcgamma receptor expression in neutrophils of patients with B-cell lymphoma treated with rituximab.
Sashida G; Takaku TI; Honda S; Ishii Y; Yamaguchi N; Sumi M; Shoji N; Gotoh A; Shimamoto T; Ito Y; Ohyashiki K
Leuk Lymphoma; 2005 May; 46(5):789-91. PubMed ID: 16019521
[No Abstract] [Full Text] [Related]
2. CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.
Kakinoki Y; Kubota H; Yamamoto Y
Int J Hematol; 2004 Jan; 79(1):55-62. PubMed ID: 14979480
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.
van der Kolk LE; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2003 Aug; 17(8):1658-64. PubMed ID: 12886256
[TBL] [Abstract][Full Text] [Related]
5. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
[TBL] [Abstract][Full Text] [Related]
6. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
Mian M; Rass C; Hutarew G; Kofler B; Fiegl M; Greil R
Leuk Lymphoma; 2006 Aug; 47(8):1683-5. PubMed ID: 16966286
[No Abstract] [Full Text] [Related]
7. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
Tomita N; Kodama F; Oshima R; Hashimoto C; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Sakai R; Fujita H; Fujisawa S; Kanamori H; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2006 Jun; 47(6):1041-7. PubMed ID: 16840195
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
Copelan E; Pohlman B; Rybicki L; Kalaycio M; Sobecks R; Andresen S; Dean R; Koo A; Chan J; Sweetenham J; Bolwell B
Bone Marrow Transplant; 2009 Jan; 43(2):101-5. PubMed ID: 18794865
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-Colony Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part II): Dose-Dependent Biodistribution and In Vivo Antitumor Efficacy in Combination with Rituximab.
Kryza D; De Crozals G; Mathe D; Taleb Sidi-Boumedine J; Janier M; Chaix C; Dumontet C
Bioconjug Chem; 2018 Mar; 29(3):804-812. PubMed ID: 29283559
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
[TBL] [Abstract][Full Text] [Related]
11. [New combination therapies in hematological malignancies].
Takeshita A; Ohno R
Gan To Kagaku Ryoho; 2000 Mar; 27(3):388-94. PubMed ID: 10740632
[TBL] [Abstract][Full Text] [Related]
12. Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine.
Kolli V; Denton K; Borra D; Pulluri M; Sharma A
Psychooncology; 2013 Jul; 22(7):1674-5. PubMed ID: 23059755
[TBL] [Abstract][Full Text] [Related]
13. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.
Schuster SJ; Venugopal P; Kern JC; McLaughlin P
Leuk Lymphoma; 2008 Sep; 49(9):1681-92. PubMed ID: 18798103
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of the high-affinity receptor for IgG (FcRI, CD64) on neutrophils in multiple myeloma.
Ohsaka A; Saionji K; Takagi S; Igari J
Hematopathol Mol Hematol; 1996; 10(3):151-60. PubMed ID: 8878733
[TBL] [Abstract][Full Text] [Related]
15. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
[No Abstract] [Full Text] [Related]
16. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
[TBL] [Abstract][Full Text] [Related]
17. In vivo administration of granulocyte colony-stimulating factor increases the surface expression of sialyl-Lewis(x) on neutrophils in healthy volunteers.
Ohsaka A; Saionji K
Acta Haematol; 1998; 100(4):187-90. PubMed ID: 9973640
[TBL] [Abstract][Full Text] [Related]
18. Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes.
Shimadoi S; Takami A; Kondo Y; Okumura H; Nakao S
Cancer Sci; 2007 Sep; 98(9):1368-72. PubMed ID: 17640305
[TBL] [Abstract][Full Text] [Related]
19. Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).
Adde M; Enblad G; Hagberg H; Sundström C; Laurell A
Med Oncol; 2006; 23(2):283-93. PubMed ID: 16720929
[TBL] [Abstract][Full Text] [Related]
20. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]